Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer.
|
| Abstract |
Aim: Evaluate quality of life (QoL) in patients with advanced non-small cell lung cancer treated with second or third line nab-paclitaxel ± durvalumab. Patients & methods: Longitudinal QoL was assessed using Lung Cancer Symptom Scale, EuroQoL Five-Dimensions Five-Levels and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core. Results: QoL was generally stable through eight treatment cycles (both arms). Clinically meaningful improvement from baseline was noted in Lung Cancer Symptom Scale (overall constitutional score and three-item index [nab-paclitaxel + durvalumab]) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core (global health status/QoL and emotional functioning [both arms] and pain [nab-paclitaxel + durvalumab]) analyses. EuroQoL Five-Dimensions Five-Levels domains were stable/improved or completely resolved at least once in 19-56% and 9-51% of patients, respectively. Conclusion: While QoL trends were promising, additional data are required to support these regimens in this setting.
|
|---|---|
| Authors | Santiago Ponce Aix, Denis Talbot, Ramaswamy Govindan, Manuel Cobo Dols, Pieter E Postmus, Conrad Lewanski, Jaafar Bennouna, Juergen R Fischer, Oscar Juan-Vidal, David J Stewart, Andrea Ardizzoni, Rafia Bhore, Marianne Wolfsteiner, Martin Reck, Teng Jin Ong, Daniel Morgensztern |
| Journal | Future oncology (London, England) (Future Oncol) Vol. 16 Issue 12 Pg. 749-762 (Apr 2020) ISSN: 1744-8301 [Electronic] England |
| PMID | 32228198 (Publication Type: Journal Article) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!